Years ago, a friend who is a highly regarded Immunologist lectured us during one of our visits to his home city Milano in Italy about the important role well written press releases play in highlighting the prominence of unknown, yet, capable biotech firms. “If not for its announced news, millions of interested people around the world, including myself, wouldn’t have heard on time about Genentech or appreciated its genius at the right time for dealing with it, working for it, or investing in it.
Two days ago, the same friend called us in New York, but this time to blame us for failing to introduce a firm called Human Longevity, which he came to hear about through its most recent issued press release he read in one of Milano’s scientific Journals.
It was me who took the phone call and guess what? Human Longevity press release was in my hand. In addition to feeling how strange was this coincidence, I wondered how the news had reached him before it reaches us then remembered the time difference between Europe and the United States. I told him that we had just learned about the press release and that we will look carefully at the firm and will post its news on our Website. We did both. Here is what we got and what we can say.
HUMAN LONGEVITY
Human Longevity’s (HLI) press release our friend referred to stated that the firm’s offering of Series B Preferred Stock has successfully raised in excess of $220 million, observing that it has previously raised $80 million in its Series A offering, which closed in the summer of 2014. The firm also remarked that closing of its Series B offering was completed with excellent results in spite of the challenging external financial markets. Human Longevity attributed the successful outcome of the offering to the strength of its science, technology and team.
“Human Longevity will build its life changing products and hire world class scientific clinical and technical leaders in order to meet its goal of revolutionizing healthcare.”
This is what J. Craig Venter, Ph.D., Co-founder and CEO, Human Longevity Company vowed the firm will do.
About the use of the proceeds, the press release continued, HLI acknowledged it will be using this round’s proceeds to fund the growth and expansion of the company and its growing line of products. These include the first Health Nucleus — HLI’s comprehensive, genomic-enhanced, research-based health center; ongoing development of the HLI Knowledge base, which already has more than 20,000 complete genomes coupled with phenotype data; the Comprehensive Cancer Program and other sequencing programs.
Investors in the Series B financing include Illumina, Celgene, GE Ventures, in addition to a strong participation from our Series A investors. These investors represent a diverse geographic pool based in the United Kingdom, Malaysia, Mexico, Australia, Kuwait, Hong Kong, and China, in addition to the US.
Human Longevity (HLI) is a genomics-based, technology-driven company said to be creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. It is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
HLI’s business also includes the HLI Health Nucleus™, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health.
Prohost Comments
We found it true what our friend, the scientists from Milano said about the importance of a press release in giving a feeling of the businesses whereabouts and their value. In this press release we have three attractive realities: The first is the fastness and successful outcome in the offering of Series B Preferred Stock, which raised in excess of $220 million. The second is learning that J. Craig Venter, Ph.D., is the Co-founder and CEO of the company. The third is the fact that among the investors in this firm are Illumina and Celgene. The fourth is learning about the nature and structure of the firm’s business, which will see contributes to “delivering the most complete picture of individual health.
That complete picture is imperative to procure in order to improve human health, prevent diseases and cure intractable deadly diseases. This complete picture is still unavailable.
Human Longevity Inc., as described, brings us hope that the missing most complete picture of individual health is now obtainable.
Human Longevity Firm Aims at Bringing the Missing Full Picture of Human Health
Years ago, a friend who is a highly regarded Immunologist lectured us during one of our visits to his home city Milano in Italy about the important role well written press releases play in highlighting the prominence of unknown, yet, capable biotech firms. “If not for its announced news, millions of interested people around the world, including myself, wouldn’t have heard on time about Genentech or appreciated its genius at the right time for dealing with it, working for it, or investing in it.
Two days ago, the same friend called us in New York, but this time to blame us for failing to introduce a firm called Human Longevity, which he came to hear about through its most recent issued press release he read in one of Milano’s scientific Journals.
It was me who took the phone call and guess what? Human Longevity press release was in my hand. In addition to feeling how strange was this coincidence, I wondered how the news had reached him before it reaches us then remembered the time difference between Europe and the United States. I told him that we had just learned about the press release and that we will look carefully at the firm and will post its news on our Website. We did both. Here is what we got and what we can say.
HUMAN LONGEVITY
Human Longevity’s (HLI) press release our friend referred to stated that the firm’s offering of Series B Preferred Stock has successfully raised in excess of $220 million, observing that it has previously raised $80 million in its Series A offering, which closed in the summer of 2014. The firm also remarked that closing of its Series B offering was completed with excellent results in spite of the challenging external financial markets. Human Longevity attributed the successful outcome of the offering to the strength of its science, technology and team.
“Human Longevity will build its life changing products and hire world class scientific clinical and technical leaders in order to meet its goal of revolutionizing healthcare.”
This is what J. Craig Venter, Ph.D., Co-founder and CEO, Human Longevity Company vowed the firm will do.
About the use of the proceeds, the press release continued, HLI acknowledged it will be using this round’s proceeds to fund the growth and expansion of the company and its growing line of products. These include the first Health Nucleus — HLI’s comprehensive, genomic-enhanced, research-based health center; ongoing development of the HLI Knowledge base, which already has more than 20,000 complete genomes coupled with phenotype data; the Comprehensive Cancer Program and other sequencing programs.
Investors in the Series B financing include Illumina, Celgene, GE Ventures, in addition to a strong participation from our Series A investors. These investors represent a diverse geographic pool based in the United Kingdom, Malaysia, Mexico, Australia, Kuwait, Hong Kong, and China, in addition to the US.
Human Longevity (HLI) is a genomics-based, technology-driven company said to be creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. It is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine.
HLI’s business also includes the HLI Health Nucleus™, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health.
Prohost Comments
We found it true what our friend, the scientists from Milano said about the importance of a press release in giving a feeling of the businesses whereabouts and their value. In this press release we have three attractive realities: The first is the fastness and successful outcome in the offering of Series B Preferred Stock, which raised in excess of $220 million. The second is learning that J. Craig Venter, Ph.D., is the Co-founder and CEO of the company. The third is the fact that among the investors in this firm are Illumina and Celgene. The fourth is learning about the nature and structure of the firm’s business, which will see contributes to “delivering the most complete picture of individual health.
That complete picture is imperative to procure in order to improve human health, prevent diseases and cure intractable deadly diseases. This complete picture is still unavailable.
Human Longevity Inc., as described, brings us hope that the missing most complete picture of individual health is now obtainable.
Other Articles